✓ Medically Reviewed Monograph

Nebivolol

Also known as / Synonyms: Nebivolol Hydrochloride, Third-Generation Beta-Blocker

Vasodilating beta-1 selective blocker that lowers blood pressure and supports chronic heart failure management via nitric oxide release.

🩺
Reviewed by Dr. Lisa Matthews, PharmD
Chief Clinical Editor · Updated November 18, 2026 · Editorial & Fact-Checking Policy
CDSCO & FDA Aligned
📋

Clinical Snapshot & Specifications

Generic Name: Nebivolol
Active Ingredient: Nebivolol Hydrochloride
Dosage Form: Tablet
Available Strengths: 2.5 mg, 5 mg, 10 mg tablets
Prescription Status: Prescription only (Schedule H / verified)
Approved Routes:
Oral
Popular Verified Brands:
Nebicard Bystolic Nodon Nebilong (India)
Regulatory Standards: CDSCO approved; Schedule H prescription drug. US FDA and EMA approved for essential hypertension and heart failure.
🎯

Approved Indications & Medical Uses

  • Treatment of essential hypertension (alone or in combination with other antihypertensive agents).
  • Adjunctive treatment of chronic stable mild-to-moderate heart failure in elderly patients (>= 70 years) with reduced or preserved ejection fraction.
  • Favored over older beta-blockers due to nitric oxide (NO)-mediated vasodilatory properties and minimal erectile dysfunction liability.
🚫

Contraindications (Do Not Use If…)

  • Severe bradycardia (heart rate < 60 bpm prior to initiation).
  • Heart block greater than first degree (second or third-degree AV block) without a functioning pacemaker.
  • Cardiogenic shock or decompensated heart failure requiring IV inotropic therapy.
  • Sick sinus syndrome.
  • Severe hepatic impairment (Child-Pugh > B).
  • Severe peripheral arterial circulatory disorders.
🛡️

Important Clinical Precautions & Warnings

  • Abrupt cessation: do not abruptly discontinue beta-blocker therapy; taper over 1 to 2 weeks to avoid rebound hypertension, angina, or myocardial infarction.
  • Bronchospastic disease: patients with asthma or COPD should generally avoid beta-blockers; if necessary, nebivolol's high beta-1 selectivity offers lower bronchospasm risk at low doses.
  • Hypoglycemia masking: may mask adrenergic warning signs of acute hypoglycemia (tachycardia, tremors).
  • Peripheral vascular disease: may precipitate or aggravate symptoms of arterial insufficiency.
  • Poor CYP2D6 metabolizers: have higher plasma levels; initiate at 2.5 mg once daily.

Special Populations (Paediatric & Geriatric Care)

Pediatric: Safety and effectiveness have not been established in patients under 18 years. Geriatric: Start at 2.5 mg once daily in patients >= 65 years. Titrate cautiously according to clinical response and heart rate.

⚡

Side Effects & Adverse Reactions

ℹ️ Common Side Effects (Usually Mild)

Headache, dizziness, fatigue, paresthesias, bradycardia, dyspnea, nausea, and peripheral edema.

🚨 Serious Side Effects — Seek Urgent Medical Care

Severe symptomatic bradycardia, AV block, acute heart failure exacerbation, bronchospasm, and cardiogenic shock.

Action: Discontinue medication and seek immediate medical attention or call emergency services if any serious symptom occurs.

🔄

Drug, Food & Substance Interactions

  • CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine): markedly increase nebivolol levels; use with caution and lower starting dose.
  • Calcium-channel blockers (verapamil, diltiazem): additive negative inotropic and chronotropic effects; heightened AV block and severe bradycardia risk.
  • Digoxin: co-administration may slow AV conduction and exacerbate bradycardia.
  • Clonidine: rebound hypertension risk upon clonidine withdrawal is accentuated by beta-blockers; withdraw beta-blocker several days before tapering clonidine.
🤰

Pregnancy & Lactation Clinical Safety

Pregnancy Safety:

Use with caution — see notes

Beta-blockers can decrease placental perfusion, resulting in intrauterine growth restriction, fetal bradycardia, and hypoglycemia in newborns. Nebivolol should be used during pregnancy only if the potential benefit justifies potential fetal risks.

Lactation & Breastfeeding:

Use with caution — see notes

Animal studies show excretion in breast milk. Due to potential serious bradycardia and hypoglycemia in nursing infants, breastfeeding is not recommended.

📦

Storage, Administration & Overdose Protocol

🌡️ Recommended Storage:

Store at 20°C to 25°C (68°F to 77°F). Protect from excessive heat and moisture.

⏱️ Missed Dose Protocol:

Take the missed dose as soon as remembered on that day. If close to the next scheduled dose, skip and resume regular timing. Do not double dose.

🛡️
Clinical & Legal Disclaimer: The clinical monographs and drug information published on 4mg.in are strictly intended for educational, clinical reference, and informational utility. They do not constitute personalized medical advice, diagnosis, or treatment regimens. Always seek the advice of a registered physician or licensed pharmacist regarding specific clinical conditions, prescription dosages, and potential contraindications. Review our comprehensive Editorial & Clinical Fact-Checking Policy.